At 4.4% CAGR, Anti-malarial Drugs Market is Anticipated to reach US$ 1,183.0 Million by 2027 | Analysis by Current Trends, Statistics Growth, Covid-19 Impact | Coherent Market Insights
The “Anti-malarial Drugs Market” report provides a quick description about market status, size, companies share, growth, opportunities and upcoming trends. This report includes the corporate profile, values that the challenges and drivers & restraints that have a serious impact on the industry analysis. The information within the report that help form the longer term projections during the forecast year. The up so far analysis to assists in understanding of the changing competitive analysis. Additionally, the market strategies including moderate growth during the years.
The research on Anti-malarial Drugs market scenario which will affect the overview the forecast period, including as opportunities, prime challenges, and current/future trends. To supply an in-depth analysis of all Anti-malarial Drugs regions included within the report into sections to supply a comprehensive competitive analysis.
Some of the leading manufacturers and suppliers of the Anti-malarial Drugs market are Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc.
Growing prevalence and incidence of malaria around the globe is primarily driving the growth of anti-malarial drugs market. According to the World Health Organization, in 2018, there were an estimated 228 million cases of malaria worldwide. Moreover, the estimated number of malaria deaths stood at 405 000 in 2018. Growing number of regulatory approval to introduce novel drugs and therapy is further expected to support the growth of anti-malarial drugs market.
For instance, in July 2018, GSK and Medicines for Malaria Venture (MMV) announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
What Anti-malarial Drugs Market Research Report Covers?
• This report covers definition, development, market status, geographical analysis of Anti-malarial Drugs market.
• Competitor analysis including all the key parameters of Anti-malarial Drugs market
• Market estimates for at least 7 years
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and proposals)
• Strategic proposals in key business portions dependent available estimations
• Company profiling with point by point systems, financials, and ongoing improvements
• Mapping of the most recent innovative headways and Supply chain patterns
Buy This Complete A Business Report With Flat US $2000 Off @
Also, growing number of partnership among key players in the market is another key factor augment growth of the market. For instance, in December 2019, Ipca Laboratories entered into a collaboration agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation, Atoguanil, a combination of atovaquone and proguanil.
In April 2018, Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting.
In March 2018, Ranbaxy launched launch of a new anti-malarial drug. Branded Synriam, the drug is the first molecule indigenously developed by a private Indian pharma player
In May 2020, The U.S. Food and Drug Administration approved artesunate for injection to treat severe malaria in adult and pediatric patients.
Middle East &Africa is expected to hold significant share in the global anti-malarial drugs market over the forecast period and this is attributed to the high prevalence of malaria in the region. According to the World Health Organization, Africa Region carries a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths
Most anti-malarial drugs used today are prepared from a group of compounds called tropomyosin or thyroxine. Antimalarials are usually employed for the treatment of malaria, while some only treat merely the symptomatic manifestations of this disease while ignoring the root cause. These contain both antimalarials and topical agents for the purpose of alleviating the pain caused by malaria. The anti-malarial drugs such as quinacrine and methotrexate both prevent the malaria-inducing malariasenic micro-cysts.
Main points in Anti-malarial Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Anti-malarial Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Anti-malarial Drugs Industry Impact
Chapter 2 Global Anti-malarial Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-malarial Drugs (Volume and Value) by Type
2.3 Global Anti-malarial Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Anti-malarial Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Anti-malarial Drugs Market Analysis
Chapter 6 East Asia Anti-malarial Drugs Market Analysis
Chapter 7 Europe Anti-malarial Drugs Market Analysis
Chapter 8 South Asia Anti-malarial Drugs Market Analysis
Chapter 9 Southeast Asia Anti-malarial Drugs Market Analysis
Chapter 10 Middle East Anti-malarial Drugs Market Analysis
Chapter 11 Africa Anti-malarial Drugs Market Analysis
Chapter 12 Oceania Anti-malarial Drugs Market Analysis
Chapter 13 South America Anti-malarial Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Anti-malarial Drugs Business
Chapter 15 Global Anti-malarial Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire